N/A Completed N=91

Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children

Respiratory Syncytial Virus Infection

Source: ClinicalTrials.gov NCT00593918 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2010

Primary outcomePrimary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04

Summary

In this project we will study the capacity for single nucleotide polymorphisms (SNP) in TLR4 gene to induce varying levels of inflammatory chemokine and cytokine production.

Outcome Measures

Outcome	Result	p-value
PRIMARY Nasal Interferon (IFN)-a2	10; 26	0.04 sig
PRIMARY Percentage of Participants With Detected Nasal Interferon (IL)-2 Cytokine Expression	0; 44	0.14

Eligibility Criteria

Inclusion Criteria

Parental or sibling history of asthma.
Child must be less than 24 months of age.
Presence of viral upper or lower respiratory tract symptoms.

Exclusion Criteria

History of recurrent wheezing requiring systemic corticosteroids.
Prior history of lung disease.
Birth < 36 weeks gestation.
Immunodeficiency
Treatment with ribavirin, systemic or inhaled corticosteroids during the RSV infection.
Congenital heart disease.
No history of parental or sibling asthma.
Less than 48 hour or more than 5 day duration of viral URI symptoms since the peak symptoms from RSV would be expected to occur from 2-5 days into course of infection.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00593918). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.